Arthritis Clinical Trials

This multicenter, open-label, single arm study will evaluate the safety and efficacy of subcutaneously administered RoActemra/Actemra (tocilizumab) in patients with active rheumatoid arthritis who are either naïve to or have an inadequate response to prior non-biologic or/and biologic DMARDs. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks. Depending on response, patients will either continue treatment with RoActemra/Actemra and discontinue methotrexate/non-biologic DMARDs or continue combination treatment with RoActemra/Actemra and methotrexate/non-biologic DMARDs for a further 28 weeks, or discontinue RoActemra/Actemra treatment.